Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $5.07 and last traded at $5.11, with a volume of 104049 shares changing hands. The stock had previously closed at $5.15.
Several analysts have recently issued reports on the company. Wedbush upped their price objective on Tango Therapeutics from $11.00 to $13.00 and gave the company an "outperform" rating in a research report on Thursday, August 8th. Cantor Fitzgerald restated an "overweight" rating on shares of Tango Therapeutics in a research report on Tuesday, July 9th. HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, October 28th. Finally, Jefferies Financial Group assumed coverage on Tango Therapeutics in a research report on Wednesday, July 17th. They issued a "buy" rating and a $19.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Tango Therapeutics presently has an average rating of "Buy" and an average target price of $15.14.
Check Out Our Latest Analysis on TNGX
The business has a fifty day moving average price of $8.17 and a 200 day moving average price of $8.41. The company has a market capitalization of $558.22 million, a PE ratio of -4.52 and a beta of 0.88.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.10. The company had revenue of $19.88 million for the quarter, compared to the consensus estimate of $7.39 million. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. Research analysts forecast that Tango Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.
In other news, insider Boxer Capital Management, Llc sold 633,000 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $6.87, for a total value of $4,348,710.00. Following the completion of the sale, the insider now owns 6,690,642 shares in the company, valued at approximately $45,964,710.54. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Rock Ventures Iv L.P. Third sold 150,000 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $10.09, for a total value of $1,513,500.00. Following the completion of the sale, the insider now owns 17,201,475 shares in the company, valued at approximately $173,562,882.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Boxer Capital Management, Llc sold 633,000 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $6.87, for a total value of $4,348,710.00. Following the completion of the sale, the insider now owns 6,690,642 shares of the company's stock, valued at approximately $45,964,710.54. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,885,400 shares of company stock worth $15,485,582. 6.30% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its stake in Tango Therapeutics by 12.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company's stock valued at $102,000 after purchasing an additional 1,426 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Tango Therapeutics by 8.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company's stock valued at $253,000 after purchasing an additional 2,218 shares in the last quarter. SG Americas Securities LLC grew its stake in Tango Therapeutics by 16.0% during the 1st quarter. SG Americas Securities LLC now owns 30,429 shares of the company's stock valued at $242,000 after purchasing an additional 4,203 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Tango Therapeutics during the 2nd quarter valued at approximately $54,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Tango Therapeutics by 32.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company's stock valued at $230,000 after purchasing an additional 7,128 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company's stock.
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.